The mTOR inhibitor temsirolimus was tried in combination with the anti-VEGF antibody bezacizumab in a clinical case series focusing on patients with neurofibromatosis 2; of the two patients on this regimen, one achieved a 33% reduction in tumor size[74]. The gene discussed is VEGFA; the disease is neoplasm.